Tryptamine Therapeutics Halts Trading Ahead of Update
Company Announcements

Tryptamine Therapeutics Halts Trading Ahead of Update

Tryptamine Therapeutics (AU:TYP) has released an update.

Tryptamine Therapeutics Limited, a biotech firm specializing in psychedelic-assisted therapies, has requested a trading halt on the ASX. The halt is in anticipation of a major update concerning their oral psilocybin study, with the halt to remain until an announcement is made or trading resumes on August 12, 2024.

For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App